Merck's consistent dividend payments over 34 years, healthy balance sheet, and attractive valuation highlight its investment ...

Biotheus’ antibody drug targets PD-L1 and VEGF, a design that’s high on drugmakers’ radars after the success of Summit ...

Merck (NYSE: MRK) recently reported its Q3 results, with revenues and earnings exceeding the street estimates.

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact – as Merck & Co has just observed in a study of Keytruda in head and neck cancer.

IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...

Avi Kapoor Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo JMP Securities initiates coverage on Summit Therapeutics, citing ...

Merck & Co’s attempts to move its checkpoint inhibitor Keytruda into prostate cancer ... on radiographic progression-free survival (rPFS) and overall survival (OS). It comes just a few weeks ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The top-line beat was led by its higher than anticipated sales of Covid-19 vaccine, while its recently approved respiratory ...

Monday, November 11, 2024: NASA's Juno spacecraft has sent back stunning photos of Jupiter, including colorful, chaotic storms swirling through the planet's atmosphere. The raw photo data captured ...